liu.seSearch for publications in DiVA
Change search
Link to record
Permanent link

Direct link
BETA
Koziorowski, Jacek
Publications (6 of 6) Show all publications
Bernhardsson, M., Sandberg, O., Ressner, M., Koziorowski, J., Malmqvist, J. & Aspenberg, P. (2018). Shining dead bone-cause for cautious interpretation of [F-18]NaF PET scans. Acta Orthopaedica, 89(1), 124-127
Open this publication in new window or tab >>Shining dead bone-cause for cautious interpretation of [F-18]NaF PET scans
Show others...
2018 (English)In: Acta Orthopaedica, ISSN 1745-3674, E-ISSN 1745-3682, Vol. 89, no 1, p. 124-127Article in journal (Refereed) Published
Abstract [en]

Background and purpose — [18F]Fluoride ([18F]NaF) PET scan is frequently used for estimation of bone healing rate and extent in cases of bone allografting and fracture healing. Some authors claim that [18F]NaF uptake is a measure of osteoblastic activity, calcium metabolism, or bone turnover. Based on the known affinity of fluoride to hydroxyapatite, we challenged this view.

Methods — 10 male rats received crushed, frozen allogeneic cortical bone fragments in a pouch in the abdominal wall on the right side, and hydroxyapatite granules on left side. [18F]NaF was injected intravenously after 7 days. 60 minutes later, the rats were killed and [18F]NaF uptake was visualized in a PET/CT scanner. Specimens were retrieved for micro CT and histology.

Results — MicroCT and histology showed no signs of new bone at the implant sites. Still, the implants showed a very high [18F]NaF uptake, on a par with the most actively growing and remodeling sites around the knee joint.

Interpretation — [18F]NaF binds with high affinity to dead bone and calcium phosphate materials. Hence, an [18F]NaF PET/CT scan does not allow for sound conclusions about new bone ingrowth into bone allograft, healing activity in long bone shaft fractures with necrotic fragments, or remodeling around calcium phosphate coated prostheses

Place, publisher, year, edition, pages
Taylor & Francis, 2018
National Category
Orthopaedics
Identifiers
urn:nbn:se:liu:diva-145121 (URN)10.1080/17453674.2017.1372097 (DOI)000423474000021 ()28914114 (PubMedID)2-s2.0-85029520826 (Scopus ID)
Available from: 2018-02-19 Created: 2018-02-19 Last updated: 2019-05-02Bibliographically approved
Todde, S., Peitl, P. K., Elsinga, P., Koziorowski, J., Ferrari, V., Ocak, E. M., . . . Behe, M. (2017). Guidance on validation and qualification of processes and operations involving radiopharmaceuticals. EJNMMI radiopharmacy and chemistry, 2(1)
Open this publication in new window or tab >>Guidance on validation and qualification of processes and operations involving radiopharmaceuticals
Show others...
2017 (English)In: EJNMMI radiopharmacy and chemistry, ISSN 2365-421X, Vol. 2, no 1Article, review/survey (Refereed) Published
Abstract [en]

Validation and qualification activities are nowadays an integral part of the day by day routine work in a radiopharmacy. This document is meant as an Appendix of Part B of the EANM "Guidelines on Good Radiopharmacy Practice (GRPP)" issued by the Radiopharmacy Committee of the EANM, covering the qualification and validation aspects related to the small-scale "in house" preparation of radiopharmaceuticals. The aim is to provide more detailed and practice-oriented guidance to those who are involved in the small-scale preparation of radiopharmaceuticals which are not intended for commercial purposes or distribution.

Place, publisher, year, edition, pages
Springer, 2017
Keywords
Qualification; Radiopharmaceuticals; Risk Assessment; Validation
National Category
Radiology, Nuclear Medicine and Medical Imaging
Identifiers
urn:nbn:se:liu:diva-146295 (URN)10.1186/s41181-017-0025-9 (DOI)29503849 (PubMedID)
Available from: 2018-04-07 Created: 2018-04-07 Last updated: 2018-04-25
Taldone, T., Zatorska, D., Ochiana, S. O., Smith-Jones, P., Koziorowski, J., Dunphy, M. P., . . . Vara Kishore Pillarsetty, N. (2016). Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71. Journal of labelled compounds & radiopharmaceuticals, 59(3), 129-132
Open this publication in new window or tab >>Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71
Show others...
2016 (English)In: Journal of labelled compounds & radiopharmaceuticals, ISSN 0362-4803, E-ISSN 1099-1344, Vol. 59, no 3, p. 129-132Article in journal (Refereed) Published
Abstract [en]

Heat shock protein 90 (Hsp90) is an ATP dependent molecular chaperone protein whose function is critical for maintaining several key proteins involved in survival and proliferation of cancer cells. PU-H71 (1), is a potent purine-scaffold based ATP pocket binding Hsp90 inhibitor which has been shown to have potent activity in a broad range of in vivo cancer models and is currently in Phase I clinical trials in patients with advanced solid malignancies, lymphomas, and myeloproliferative neoplasms. In this report, we describe the radiosynthesis of [I-124]-PU-H71(5); this was synthesized from the corresponding Boc-protected stannane precursor 3 by iododestannylation with [I-124]-NaI using chloramine-T as an oxidant for 2min, followed by Boc deprotection with 6 N HCl at 50 degrees C for 30min to yield the final compound. The final product 5 was purified using HPLC and was isolated with an overall yield of 55 +/- 6% (n=6, isolated) from 3, and >98% purity and an average specific activity of 980mCi/mu mol. Our report sets the stage for the introduction of [I-124]-PU-H71 as a potential non-invasive probe for understanding biodistribution and pharmacokinetics of PU-H71 in living subjects using positron emission tomography imaging.

Place, publisher, year, edition, pages
WILEY-BLACKWELL, 2016
Keywords
iodine-124; PU-H71; purine; heat shock protein 90; PET; radiotracer; cancer; iododestannylation
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-127055 (URN)10.1002/jlcr.3369 (DOI)000372328200008 ()26806023 (PubMedID)
Note

Funding Agencies|David Rubenstein Center for Pancreatic Cancer Research; Susan G. Komen for the Cure; Department of Defense [PDF-BC093421]; MSKCC Brain Tumor Center; NIH Cancer Center Support Grant [2 P30 CA008748-48]; [P50-CA86438]; [R01 CA172546]; [R01 CA155226]; [P50 CA192937]; [R03-BC085588]

Available from: 2016-04-13 Created: 2016-04-13 Last updated: 2017-04-24
Joshi, S. M., de Cozar, A., Gomez-Vallejo, V., Koziorowski, J., Llop, J. & Cossio, F. P. (2015). Synthesis of radiolabelled aryl azides from diazonium salts: experimental and computational results permit the identification of the preferred mechanism. Chemical Communications, 51(43), 8954-8957
Open this publication in new window or tab >>Synthesis of radiolabelled aryl azides from diazonium salts: experimental and computational results permit the identification of the preferred mechanism
Show others...
2015 (English)In: Chemical Communications, ISSN 1359-7345, E-ISSN 1364-548X, Vol. 51, no 43, p. 8954-8957Article in journal (Refereed) Published
Abstract [en]

Experimental and computational studies on the formation of aryl azides from the corresponding diazonium salts support a stepwise mechanism via acyclic zwitterionic intermediates. The low energy barriers associated with both transition structures are compatible with very fast and efficient processes, thus making this method suitable for the chemical synthesis of radiolabelled aryl azides.

Place, publisher, year, edition, pages
Royal Society of Chemistry, 2015
National Category
Chemical Sciences
Identifiers
urn:nbn:se:liu:diva-119270 (URN)10.1039/c5cc01913c (DOI)000354478700013 ()25929958 (PubMedID)
Note

Funding Agencies|RADIOMI project (EU FP7-PEOPLE-ITN-RADIOMI); Ministerio de Economia y Competitividad (MINECO) of Spain; FEDER [CTQ2013-45415-P]; University of the Basque Country (UPV/EHU) [UFI11/22 QOSYC]; Basque Government (GV/EJ) [IT-324-07]

Available from: 2015-06-12 Created: 2015-06-12 Last updated: 2017-12-04
Todde, S., Windhorst, A. D., Behe, M., Bormans, G., Decristoforo, C., Faivre-Chauvet, A., . . . Elsinga, P. H. (2014). EANM guideline for the preparation of an Investigational Medicinal Product Dossier (IMPD). European Journal of Nuclear Medicine and Molecular Imaging, 41(11), 2175-2185
Open this publication in new window or tab >>EANM guideline for the preparation of an Investigational Medicinal Product Dossier (IMPD)
Show others...
2014 (English)In: European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, E-ISSN 1619-7089, Vol. 41, no 11, p. 2175-2185Article in journal (Refereed) Published
Abstract [en]

The preparation of an Investigational Medicinal Product Dossier (IMPD) for a radiopharmaceutical to be used in a clinical trial is a challenging proposition for radiopharmaceutical scientists working in small-scale radiopharmacies. In addition to the vast quantity of information to be assembled, the structure of a standard IMPD is not well suited to the special characteristics of radiopharmaceuticals. This guideline aims to take radiopharmaceutical scientists through the practicalities of preparing an IMPD, in particular giving advice where the standard format is not suitable. Examples of generic IMPDs for three classes of radiopharmaceuticals are given: a small molecule, a kit-based diagnostic test and a therapeutic radiopharmaceutical.

Place, publisher, year, edition, pages
Springer Verlag (Germany), 2014
Keywords
Radiopharmaceutical; Clinical trial; Investigational medicinal product; Guideline
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-112171 (URN)10.1007/s00259-014-2866-8 (DOI)000343051700028 ()25081821 (PubMedID)
Available from: 2014-11-18 Created: 2014-11-18 Last updated: 2017-12-05
Aerts, J., Ballinger, J. R., Behe, M., Decristoforo, C., Elsinga, P. H., Faivre-Chauvet, A., . . . Koziorowski, J. (2014). Guidance on current good radiopharmacy practice for the small-scale preparation of radiopharmaceuticals using automated modules: a European perspective. Journal of labelled compounds & radiopharmaceuticals, 57(10), 615-620
Open this publication in new window or tab >>Guidance on current good radiopharmacy practice for the small-scale preparation of radiopharmaceuticals using automated modules: a European perspective
Show others...
2014 (English)In: Journal of labelled compounds & radiopharmaceuticals, ISSN 0362-4803, E-ISSN 1099-1344, Vol. 57, no 10, p. 615-620Article in journal (Refereed) Published
Abstract [en]

This document is meant to complement Part B of the EANM Guidelines on current good radiopharmacy practice (cGRPP) in the preparation of radiopharmaceuticals issued by the Radiopharmacy Committee of the European Association of Nuclear Medicine, covering small-scale in-house preparation of radiopharmaceuticals with automated modules. The aim is to provide more detailed and practice-oriented guidance to those who are involved in the small-scale preparation of radiopharmaceuticals, which are not intended for commercial purposes or distribution.

Place, publisher, year, edition, pages
Wiley-Blackwell, 2014
Keywords
radiopharmaceutical; positron emission tomography; single-photon emission computed tomography; process validation; automated radiosynthesis module
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-112068 (URN)10.1002/jlcr.3227 (DOI)000342834100005 ()25196257 (PubMedID)
Available from: 2014-11-17 Created: 2014-11-13 Last updated: 2017-12-05Bibliographically approved
Organisations

Search in DiVA

Show all publications